An Initial Report of Memory Avoidance Whole Brain Radiotherapy (MA-WBRT) To Treat Brain Metastases
Clicks: 2
ID: 324914
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
2 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #35 of 104 articles by views in Neuro-Oncology Advances
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Hippocampal avoidance whole brain radiotherapy (HA-WBRT) with memantine is standard of care for patients with extensive brain metastases requiring radiation. However, other brain structures have critical memory and cognition roles including the corpus callosum, fornix, amygdala, hypothalamus, and pituitary. A subset of patients enrolled on a Phase 2 Randomized Controlled Trial received an advanced “memory-avoidance” WBRT (MA-WBRT) approach that spared these substructures in addition to the hippocampus. Methods Patients with > 15 brain metastases were enrolled in the ATHENA Trial and received MA-WBRT. All patients received 30 Gy in 10 fractions of MA-WBRT and were prescribed memantine. Cognition was measured by Hopkins Verbal Learning Test-Revised, Controlled Oral Word Association Test, and Trail Making Test A/B, with cognitive decline defined as decline on at least one assessment using reliable change index. Findings Between August 2022 and May 2024, 29 patients were prescribed MA-WBRT. Decline in neurocognitive function at three and six months for patients receiving MA-WBRT was 17.2% and 48.3%, respectively. There was only one failure in a memory avoidance substructure (occurring in the right fornix 10 months after enrollment), and this was associated with concurrent distant intracranial failure outside the memory avoidance zone. Interpretation The cognitive decline rates of 17.2% and 48.3% at three and six months for patients receiving MA-WBRT compare favorably to the three and six-month cognitive decline rates of 50% and 60% seen on NRG CC001. A direct comparison of MA-WBRT plus memantine vs. HA-WBRT plus memantine is forthcoming in a randomized phase 2 trial (NCT07248228).
| Reference Key |
openalex_W7202383817
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Joshua D. Palmer, Erica Dawson, Yilun Sun, Jiawei Yu, Khaled Dibs, Alex R. Ritter, Daniel Boulter, Ansel P. Nalin, Raj Singh, Sasha Beyer, Simeng Zhu, Dukagjin Blakaj, J.C. Grecula, Raju R. Raval, Shayla Vazquez, Samantha Whitman, Carolyn J. Presley, Clement Pillainayagam, Pierre Giglio, Evan Thomas, Haley K. Perlow |
| Journal | Neuro-Oncology Advances |
| Year | 2026 |
| DOI |
10.1093/noajnl/vdag211
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.